Characteristics of Mast Cells in Mastocytosis
NCT00001356 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 300
Last updated 2008-03-04
Summary
This study will determine what growth factors are involved in promoting and inhibiting mastocytosis-an abnormal increase of mast cells in one or more organ systems. Mast cells release chemicals that can cause itching, blisters, flushing, bone pain, and abdominal pain. Little is known about the disease and there is no cure. Steroids and antihistamines can help reduce some symptoms.
Patients from birth to 80 years of age with increased mast cells in at least one organ system may be eligible for this 3-year study. Family members may also be enrolled for genetic testing.
Patients will be evaluated yearly at the NIH Clinical Center with the following tests and procedures:
* Medical history and physical examination.
* Blood samples.
* Laboratory blood tests, as medically indicated.
* Bone marrow aspiration and biopsy - For the bone marrow aspiration and biopsy, the back hipbone is punctured with a sterile needle. Five milliliters (1 teaspoon) of marrow is withdrawn through a syringe and a 1/2-inch piece of tissue is extracted with a special needle.
The blood and bone marrow samples will be used for clinical care and for research to determine if mastocytosis is due to mast cell growth factors or genetic changes.
Patients who require further evaluation and tests will have recommendations made to their primary physician. Any patient who requires immediate treatment will be admitted to the hospital. Standard medical treatment may include antihistamines for itching; steroids for severe abdominal symptoms such as cramping, diarrhea, and evidence of increased mast cells determined by an upper GI study; and adrenaline for anaphylactic shock. Patients who do not respond to conventional treatment may be offered participation in an experimental therapy study.
Participating family members will have a medical history and a blood sample drawn to look for genetic abnormalities.
Conditions
- Mastocytosis
Sponsors & Collaborators
-
National Institute of Allergy and Infectious Diseases (NIAID)
lead NIH
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 1993-05-31
- Completion
- 2002-05-31
Countries
- United States
Study Locations
More Related Trials
-
Explore the Mechanisms of Pruritus in Bullous Pemphigoid Patients During Remission
NCT01265082 ·Status: UNKNOWN
-
Ocular and Palpebral Manifestations of Mastocytosis (MOOMA)
NCT04978740 ·Status: COMPLETED ·Phase: NA
-
A Registry for Patients With Systemic Mastocytosis in China
NCT06013683 ·Status: RECRUITING
-
Assessment of Macrophage Activation syndromE in STill's Disease in Italy
NCT06992505 ·Status: COMPLETED
-
Evaluation of Response of Dasatinib to Treat Mastocytosis
NCT00979160 ·Status: UNKNOWN ·Phase: PHASE2
-
Natural History of Hypereosinophilia and Hypereosinophilic Syndromes
NCT04018118 ·Status: RECRUITING
-
Efficacy and Safety of ACZ885 in Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease
NCT00685373 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Subcutaneous Injection of Low-dose rhGM-CSF +/- WLL in PAP.
NCT01983657 ·Status: UNKNOWN ·Phase: PHASE2
-
Steroids and Methotrexate to Treat Systemic Vasculitis
NCT00001256 ·Status: COMPLETED ·Phase: PHASE2
-
Characterization of the Fungal Origins in the Autoimmune Polyendocrinopathy of Type 1 Compared With the Autoimmune Polyendocrinopathies of Type 2
NCT03800056 ·Status: TERMINATED
-
Cyclophosphamide and Prednisone Followed by Methotrexate To Treat Vasculitides
NCT00001473 ·Status: COMPLETED
-
Clinical Characteristics of Aquagenic Pruritus in Patients With Myeloproliferative Neoplasms
NCT03688490 ·Status: COMPLETED
-
Mycophenolate Mofetil to Treat Wegener's Granulomatosis and Related Vascular Inflammatory Conditions
NCT00001764 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Autoimmune Lymphoproliferative Syndrome (ALPS)
NCT00001350 ·Status: RECRUITING
-
Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease
NCT01576367 ·Status: COMPLETED ·Phase: PHASE3
-
International Registry for Patients With Castleman Disease
NCT02817997 ·Status: RECRUITING
-
Methotrexate as Remission Maintenance Therapy After Remission-Induction With Tocilizumab and Glucocorticoids in Giant Cell Arteritis
NCT05623592 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Treatment of Renal Sarcoidosis by Methylprednisolone Bolus
NCT01652417 ·Status: TERMINATED ·Phase: NA
-
New Candidate Criteria for Diagnosis of Macrophage Activation Syndrome
NCT01095146 ·Status: UNKNOWN
-
Treatment With High Dose Methotrexate in Patients With Eosinophilic Fasciitis
NCT00441961 ·Status: COMPLETED ·Phase: NA
-
Study of Mycobacterial Infections
NCT00018044 ·Status: RECRUITING
-
Phase 2 Study of Human Umbilical Cord Derived Mesenchymal Stem Cell for the Treatment of Lupus Nephritis
NCT01539902 ·Status: UNKNOWN ·Phase: PHASE2
-
Safety and Efficacy of High-dose Leukocytapheresis Using a Large Filter in Refractory Asthma
NCT00888472 ·Status: COMPLETED ·Phase: NA
-
Safety and Tolerability of Rilonacept in Muckle-Wells Syndrome (MWS) or Schnitzler Syndrome (SchS)
NCT01045772 ·Status: COMPLETED ·Phase: PHASE2
-
Pharmacokinetics Study of Mycophenolic Acid in Patients With an Autoimmune Bullous Dermatose, Pemphigus or Cicatricial Pemphigoid.
NCT02993133 ·Status: COMPLETED ·Phase: PHASE3